The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Table 3 Percent completing M6 and probability of retention at M3 and M6 by baseline medical cannabis use in 1011 participants

Baseline cannabis use	Completed M6 (%)	Kaplan–Meier estimator
		Probability of remaining in study
		M3	M6	P
Cannabis use per week (g)				0.567
< 5	211/495 (42.6)	0.74	0.43
≥ 5	208/505 (41.2)	0.72	0.41
Frequency of cannabis use per week				0.587
< 14	186/428 (43.5)	0.72	0.43
≥ 14	233/571 (40.8)	0.73	0.41
Currently using Tilray extract products				0.751
No	165/381 (43.3)	0.71	0.43
Yes	254/619 (41.0)	0.74	0.41
Preferred type of cannabis				0.044
THC	105/239 (43.9)	0.72	0.44
High CBD	174/461 (37.7)	0.73	0.38
No preference	139/286 (48.6)	0.74	0.49
Primary method of use				< 0.001
Vaporizer—cannabis flower	99/167 (59.3)	0.80	0.59
Vaporizer/nail—cannabis extracts	2/10 (20.0)	0.50	0.20
Joint	73/194 (37.6)	0.71	0.38
Oral	209/546 (38.3)	0.72	0.38
Pipe	11/33 (33.3)	0.58	0.33
Waterpipe/bong	18/35 (51.4)	0.80	0.51
Topical	5/11 (45.5)	0.82	0.45
Primary method of use				0.027
Inhaled	203/439 (46.2)	0.74	0.46
Orally ingested	209/546 (38.3)	0.72	0.38

ISSN: 2522-5782